Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential CD19 and CD20 CAR-T Therapy for DLBCL
NCT02737085Phase 2Unknown
- Sponsor
- Southwest Health System
- Start
- Mar 2016
- Primary completion
- Dec 2019
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of anti-CD19 CAR-T cells, anti-CD20 CAR-T cells (Southwest Hospital) in diffuse large B-cell lymphoma (DLBCL), sponsored by Southwest Health System. Status: unknown.
02
Drugs
anti-CD19 CAR-T cellsanti-CD20 CAR-T cells (Southwest Hospital)
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02737085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737085.